The objective of the current study was to compare drug survival of ixekizumab to that of TNF inhibitors (TNFi) and non‐ixekizumab IL‐17 inhibitors (IL‐17i) among real‐world patients with PsO in the Corrona Psoriasis Registry. This evidence concerns the gene TNF and psoriasis.